NeuroBo Pharmaceuticals (NRBO) has issued an announcement.
NeuroBo Pharmaceuticals, Inc. has joined forces with Dong-A ST Co. Ltd. and ImmunoForge to create a new long-acting, once-monthly drug formulation for DA-1726, a promising dual-action diabetes treatment. This collaboration will leverage ImmunoForge’s innovative ELP technology to extend the medication’s active life. While this news is promising, the company cautions that these forward-looking statements are not assured and actual outcomes may vary.
For a thorough assessment of NRBO stock, go to TipRanks’ Stock Analysis page.
